Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2025)

Crinetics Pharmaceuticals has reported Current Assets over the past 9 years, most recently at $1.0 billion for Q4 2025.

  • Quarterly results put Current Assets at $1.0 billion for Q4 2025, down 23.78% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (down 23.78% YoY), and the annual figure for FY2025 was $1.0 billion, down 23.78%.
  • Current Assets for Q4 2025 was $1.0 billion at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Current Assets for CRNX hit a ceiling of $1.4 billion in Q4 2024 and a floor of $157.8 million in Q1 2021.
  • Median Current Assets over the past 5 years was $495.2 million (2022), compared with a mean of $642.4 million.
  • Biggest five-year swings in Current Assets: plummeted 31.58% in 2023 and later soared 207.14% in 2024.
  • Crinetics Pharmaceuticals' Current Assets stood at $344.7 million in 2021, then increased by 0.13% to $345.2 million in 2022, then skyrocketed by 66.33% to $574.2 million in 2023, then skyrocketed by 139.55% to $1.4 billion in 2024, then fell by 23.78% to $1.0 billion in 2025.
  • The last three reported values for Current Assets were $1.0 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.